Sickle cell anemia

Active Research Protocols

  1. 01-H-0088 – Determining the Prevalence and Prognosis of Secondary Pulmonary Hypertension in Adult Patients with Sickle Cell Anemia
  2. 01-H-0122 – Collection and Storage of Umbilical Cord Hematopoietic Stem Cells for Sickle Cell Disease Therapy
  3. 01-H-0223 – Inhaled Nitric Oxide and Transfusion Therapy for Patients with Sickle Cell Anemia and Secondary Pulmonary Hypertension
  4. 03-CC-0127 – Evaluation of Potential Synergy of Combining Hydroxyurea with Nitric Oxide Donors on Fetal Hemoglobin Synthesis in Patients with Sickle Cell Anemia
  5. 03-H-0015 – Collection of Blood from Volunteers and Patients for Studies of Endothelial Function and Systemic Inflammation
  6. 03-H-0170 – Non-Myeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation For Severe Congenital Anemias Including Sickle Cell Disease, Thalassemia, and Diamond Blackfan Anemia
  7. 04-CC-0032 – Atorvastatin Therapy To Improve Endothelial Function in Sickle Cell Disease
  8. 04-H-0161 – Studies of the Natural History of Sickle Cell Disease and Other Hemolytic Disorders
  9. 05-H-0016 – Therapeutic Application of Intravascular Nitrite for Sickle Cell Disease
  10. 05-H-0019 – A Prospective, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis
  11. 06-H-0054 – Evaluation of Synergy of Combining Hydroxyurea with Recombinant Human Erythropoietin Glycoform Alpha (rhu Erythropoietin-alpha) on Fetal Hemoglobin Synthesis in Patients with Sickle Cell Anemia
  12. 06-H-0202 – Cardiopulmonary Function Assessment and NO Based Therapies for Patients with Hemolysis-Associated Pulmonary Hypertension
  13. 07-CC-0011 – Hypnosis as a Pain and Symptom Management Strategy in Patients with Sickle Cell Disease
  14. 07-H-0177 – Treatment of Pulmonary Hypertension and Sickle Cell Disease with Sildenafil Therapy
  15. 07-H-0181 – Pulmonary Hypertension and the Hypoxic Response in SCD
  16. 07-H-0196 – Niacin Therapy to Improve Endothelial Function in Sickle Cell Disease
  17. 08-DK-0004 – High Throughput Screening of Compound Libraries to Discover a Drug for the Treatment of Sickle Cell Disease
  18. 08-H-0156 – Screening of Subjects to Determine Eligibility to Safely Participate in Blood Disorders Studies
  19. 09-H-0225 – Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease and Beta-Thalassemia
  20. 10-H-0031 – THE IMPROVE TRIAL: Improving Pain Management and Outcomes with Various Strategies of Patient-Controlled Analgesia (PCA)
  21. 11-H-0121 – A Phase I Study of the Use of Topical Sodium Nitrite for Chronic Leg Ulcers in Adult Patients with Hemolytic Disorders
  22. 11-H-0184 – An Extended Phase II Study of Decitabine in Subjects with High Risk Sickle Cell Disease
  23. 11-H-0252 – Exploratory Studies of Psychophysical Pain Phenotyping and Genetic Variability in Sickle Cell Disease
  24. 11-NR-0189 – Biochemical and Genetic Mechanisms for Etiology of Sickle Cell Pain
  25. 12-H-0069 – End-Alveolar Carbon Monoxide as a Measure of Erythrocyte Survival and Hemolytic Severity in Sickle Cell Disease
  26. 12-H-0101 – Measurement of the Reactive Hyperemia Index in Sickle Cell Patients During Pain Crisis and After Recovery
  27. 12-H-0124 – Microvascular and Cardiac Dysfunction in Sickle Cell Disease
  28. 12-H-0127 – A Phase 1, Placebo-Controlled, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating, Single or Multiple Oral Doses of Aes-103 in Subjects with Stable Sickle Cell Disease
  29. 84-H-0029 – Effect of Hydroxyurea on Fetal Hemoglobin Synthesis in Patients with Sickle Cell Anemia
NOTE: PDF documents require the free
Adobe Reader.
This page was last updated: January 24, 2014